Literature DB >> 27067965

Cancer associated thrombosis: risk factors and outcomes.

Sabine Eichinger1.   

Abstract

Deep vein thrombosis of the leg and pulmonary embolism are frequent diseases and cancer is one of their most important risk factors. Patients with cancer also have a higher prevalence of venous thrombosis located in other parts than in the legs and/or in unusual sites including upper extremity, splanchnic or cerebral veins. Cancer also affects the risk of arterial thrombotic events particularly in patients with myeloproliferative neoplasms and in vascular endothelial growth factor receptor inhibitor recipients. Several risk factors need to interact to trigger thrombosis. In addition to common risk factors such as surgery, hospitalisation, infection and genetic coagulation disorders, the thrombotic risk is also driven and modified by cancer-specific factors including type, histology, and stage of the malignancy, cancer treatment and certain biomarkers. A venous thrombotic event in a cancer patient has serious consequences as the risk of recurrent thrombosis, the risk of bleeding during anticoagulation and hospitalisation rates are all increased. Survival of cancer patients with thrombosis is worse compared to that of cancer patients without thrombosis, and thrombosis is a leading direct cause of death in cancer patients.
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Mortality; Outcome; Risk factors; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27067965     DOI: 10.1016/S0049-3848(16)30092-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  18 in total

1.  Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

Authors:  Tuukka A Helin; Lotta Joutsi-Korhonen; Heidi Asmundela; Mikko Niemi; Arto Orpana; Riitta Lassila
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

2.  ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.

Authors:  Emanuel Raschi; Igor Diemberger; Benilde Cosmi; Fabrizio De Ponti
Journal:  Intern Emerg Med       Date:  2017-09-23       Impact factor: 3.397

Review 3.  Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.

Authors:  Laura M Attard; Alex Gatt; Laurent Bertoletti; Aurelien Delluc; Nicoletta Riva
Journal:  Vasc Health Risk Manag       Date:  2022-10-13

4.  Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE.

Authors:  Omri Cohen; Walter Ageno; Alfredo E Farjat; Alexander G G Turpie; Jeffrey I Weitz; Sylvia Haas; Shinya Goto; Samuel Z Goldhaber; Pantep Angchaisuksiri; Harry Gibbs; Peter MacCallum; Gloria Kayani; Sebastian Schellong; Henri Bounameaux; Lorenzo G Mantovani; Paolo Prandoni; Ajay K Kakkar
Journal:  J Thromb Haemost       Date:  2021-11-08       Impact factor: 16.036

Review 5.  Cancer and Thrombotic Risk: The Platelet Paradigm.

Authors:  Elizabeth C Lee; Scott J Cameron
Journal:  Front Cardiovasc Med       Date:  2017-11-07

6.  Dimethyl 2,2'-[2,2'-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect.

Authors:  Yaonan Wang; Haiyan Chen; Xiaoyi Zhang; Lin Gui; Jianhui Wu; Qiqi Feng; Shiqi Peng; Ming Zhao
Journal:  Int J Nanomedicine       Date:  2018-11-22

Review 7.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

8.  Effect of dexmedetomidine on blood coagulation in patients undergoing radical gastrectomy under general anesthesia: A prospective, randomized controlled clinical trial.

Authors:  Zheng Chen; Dong-Hua Shao; Zu-Min Mao; Lei-Lei Shi; Xiao-Dong Ma; Da-Peng Zhang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

9.  New diagnosis of cancer and the risk of subsequent cerebrovascular events.

Authors:  Babak B Navi; George Howard; Virginia J Howard; Hong Zhao; Suzanne E Judd; Mitchell S V Elkind; Costantino Iadecola; Lisa M DeAngelis; Hooman Kamel; Peter M Okin; Susan Gilchrist; Elsayed Z Soliman; Mary Cushman; Paul Muntner
Journal:  Neurology       Date:  2018-05-04       Impact factor: 9.910

10.  Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study.

Authors:  Adeline Heraudeau; Aurélien Delluc; Mickaël Le Henaff; Karine Lacut; Christophe Leroyer; Benoit Desrues; Francis Couturaud; Cécile Tromeur
Journal:  PLoS One       Date:  2018-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.